^
Association details:
| Biomarker: | CD276 overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | ifinatamab deruxtecan (DS-7300) (Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
513O - A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors
Published date:
09/13/2021
Excerpt:
...report preliminary results from a phase 1/2 trial of DS-7300 in pts with advanced solid tumors....Baseline B7-H3 expression was highly prevalent in the study population....28 pts had stable disease....DS-7300 was generally well tolerated with early signs of clinical activity, including objective responses...
Trial ID:
Source:
Title:
DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models
Published date:
04/01/2022
Excerpt:
Moreover, DS-7300a demonstrated potent in vivo antitumor activities in high-B7-H3 tumor xenograft models, including various tumor types of high-B7-H3 PDX models....Therefore, DS-7300a may be effective in treating patients with B7-H3-expressing solid tumors in a clinical setting.
DOI:
10.1158/1535-7163.MCT-21-0554
Source:
Title:
DS-7300a, a novel B7-H3-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, exhibits potent anti-tumor effects in nonclinical models
Published date:
10/09/2020
Excerpt:
DS-7300a demonstrated potent anti-tumor activity in high-B7-H3 tumors in nonclinical models including PDX models used in this study. Therefore, DS-7300a could provide a new therapeutic opportunity for patients with B7-H3-expressing solid tumors at clinical setting.
